Chronic Lymphocytic Leukemia News
At a follow-up of almost 4 years, over two-thirds of patients randomly assigned to receive ofatumumab crossed over to receive ibrutinib.
Relative increases in health care costs associated with disease progression were more than 30% in subgroups of patients with CLL and NHL.
Sequential multiple assignment randomized trials (SMART) have an adaptive design based on patient response to therapy.
According to results of an exploratory study, patients with Richter transformation may benefit from treatment with ibrutinib plus nivolumab.
When used as a fixed-duration venetoclax-rituximab combination, 62% of patients achieved an undetectable minimal residual disease level in peripheral blood.
Researchers identified a single heterozygous nucleotide variant that confers resistance to venetoclax, and it’s a mutation that may be detected years before clinical relapse occurs.
Three-year outcomes reveal a new standard of care in patients with CLL who are younger than 70.
Although PFS with ibrutinib-containing regimens was favorable compared with bendamustine rituximab, overall survival was not different across the study arms.
Although CAR-T alone has shown utility in CLL, evidence suggests the addition of ibrutinib could improve the durability of remission.
Favorable data on liso-cel bolsters its chances of moving into further stages of development, provided complete responses remain durable.
Cell surface antigen Siglec-6 was broadly expressed in chronic lymphocytic leukemia after transplantation, suggesting a new potential drug target.
There are several novel agents, such as ibrutinib, idelalisib, and venetoclax, that could improve outcomes in CLL patients with 17p deletions and TP53 mutations.
AID is a mutator enzyme that plays an essential role for somatic hypermutation and class switch recombination during effective adaptive immune responses.
A regimen showed favorable minimal residual disease negativity in patients with high-risk CLL, allowing many to pursue transplantation.
Immune changes in the tumor microenvironment were associated with clinical response to lenalidomide in patients with chronic lymphocytic leukemia.
High comorbidity burden was associated with worse survival outcomes in patients with chronic lymphocytic leukemia who were treated with ibrutinib.
Duvelisib improved PFS by more than 3 months compared with ofatumumab, the current standard of care, in relapsed or refractory CLL and SLL.
In patients with chronic lymphocytic leukemia, a lower ibrutinib dose appears to confer sufficient biological activity, but further study is needed.
Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.
Transplant-naive patients were more likely to achieve an optimal drug response — but were also more prone to severe cytokine release syndrome and neurotoxicity.